

## Road map for HTA research

This road map provides a concise overview of the costs and funding sources of HTA research into AI applications.

### How can I provide insight into the added value of my product?

- a) My product leads to costs and benefits in the long term.
- b) My product leads to benefits outside of the purchasing institution.
- c) My product mainly results in health gains and does not save costs.
- d) It is desirable that the basic health insurance reimburse my product; to this end, it needs to be assessed by the National Health Care Institute.

No

A business case is sufficient

Yes

It is useful to carry out an HTA\*

\*While an HTA offers an objective analysis of an intervention's added value, a positive HTA is not a guarantee for the uptake of an AI application in practice.

### What is the goal of the HTA and what are its costs or estimated costs?

*Costs of steps 'Carry out the cost-effectiveness analysis' and 'Report results' from the 'Step-by-step plan for carrying out an economic evaluation' appendix*

For personal insight, not for external use

€10,000 – €30,000

Informing external parties (e.g. healthcare providers, health insurers)

€30,000 – €100,000

Application for reimbursement (national or international)

> €100,000

### What are public funding sources for HTAs in the Netherlands?

ZonMw has the following grants for HTA research: Efficiency Study/BeNeFIT/Grant scheme for promising care/Good Use of Devices in Healthcare/2021-2024 HTA methodology (provided there is a methodologically innovative component).

### What relevant public/private partnerships for HTA are there in the Netherlands?

Life Science & Health Top Sector (Health Holland)

Health Innovation Netherlands 'Round Table service'

HTA groups in Dutch universities (<https://www.nvtag.nl/hta-in-nederland/>)

For the implementation of the HTA and the decisions involved, we refer to the appendix 'Step-by-step plan for carrying out an economic evaluation'